跳至主要内容
临床试验/NCT00950456
NCT00950456已完成不适用

A Prospective Non-Interventional Observational Study to Assess the Safety of Two Vaccinations of a Vero Cell-Derived, Whole Virus H1N1 Pandemic Influenza Vaccine in Subjects Exposed to the Vaccine Through Policies by Governments or Health Authorities

Resilience Government Services, Inc.7 个研究点 分布在 1 个国家目标入组 3,216 人开始时间: 2009年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
3,216
试验地点
7

研究概览

简要总结

The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse events in all vaccinated subjects.

研究设计

研究类型
Observational
观察模型
Ecologic Or Community
时间视角
Prospective

入排标准

年龄范围
2 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects, per indication on license or per official vaccine recommendations, will be eligible for participation in this study if:
  • They will be administered CELVAPAN (= Baxter´s H1N1 pandemic influenza vaccine)
  • They are 2 months of age or older at the time of first vaccine administration
  • Their medical history is available
  • The investigator believes they will comply with the foreseen vaccination schedule and will reliably observe signs or symptoms of adverse events during the observational period
  • They and/or their parent(s)/legal guardian(s) provide written informed consent, and assent where appropriate, prior to study entry according to national law

排除标准

  • Male and female subjects will be excluded from participation in this study if:
  • They have already been administered another H1N1 pandemic vaccine
  • They have any contraindication to vaccination (as per the Summary of Product Characteristics and/or relevant national immunization guidelines)

研究者

申办方类型
Industry

研究点 (7)

Loading locations...

相似试验